How the "Blood Test for Cancer" Performs in the Real World: An Analysis of 1,500 Liquid Biopsy Cases

Thursday, April 20, 7:00pm ET

60-Minute Webinar with Q&A

If you are unable to make this date and time, please submit a registration anyway. A RACE-approved online course will be created using the archived recording of the webinar.

Blood-based liquid biopsy using next-generation sequencing (NGS) became clinically available in May 2021. Since that time, the test has been ordered for thousands of patients, primarily as a screening tool for dogs at higher risk of cancer as well as an aid in diagnosis for dogs for which there is a clinical suspicion of cancer.

Join Todd Cohen, DVM, DACVIM (Small Animal Internal Medicine), for a review of data from a recent publication in the Journal of the American Veterinary Medical Association (JAVMA) analyzing a cohort of 1,500 consecutive liquid biopsy tests received for commercial testing at one clinical laboratory. The webinar will include a discussion of ordering patterns, positivity rates, and patient outcome data, along with how this data can be used to discuss liquid biopsy testing with clients. A series of interesting case studies will be presented, exploring the use of this testing in a variety of clinical settings.

Questions about this webinar?

This program #939607 is approved by the AAVSB RACE to offer a total of 1.00 CE credit for veterinarians and technicians.

Register Now

This webinar has already occurred and registration is now closed.